Literature DB >> 1826744

Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.

P D Leeson1, R Baker, R W Carling, N R Curtis, K W Moore, B J Williams, A C Foster, A E Donald, J A Kemp, G R Marshall.   

Abstract

Derivatives of the nonselective excitatory amino acid antagonist kynurenic acid (4-oxo-1,4-dihydroquinoline-2-carboxylic acid, 1) have been synthesized and evaluated for in vitro antagonist activity at the excitatory amino acid receptors sensitive to N-methyl-D-aspartic acid (NMDA), quisqualic acid (QUIS or AMPA), and kainic acid (KA). Introduction of substituents at the 5-, 7-, and 5,7-positions resulted in analogues having selective NMDA antagonist action, as a result of blockade of the glycine modulatory (or coagonist) site on the NMDA receptor. Regression analysis suggested a requirement for optimally sized, hydrophobic 5- and 7-substituents, with bulk tolerance being greater at the 5-position. Optimization led to the 5-iodo-7-chloro derivative (53), which is the most potent and selective glycine/NMDA antagonist to date (IC50 vs [3H]glycine binding, 32 nM; IC50's for other excitatory amino acid receptor sites, greater than 100 microM). Substitution of 1 at the 6-position resulted in compounds having selective non-NMDA antagonism and 8-substituted compounds were inactive at all receptors. The retention of glycine/NMDA antagonist activity in heterocyclic ring modified analogues, such as the oxanilide 69 and the 2-carboxybenzimidazole 70, suggests that the 4-oxo tautomer of 1 and its derivatives is required for activity. Structurally related quinoxaline-2,3-diones are also glycine/NMDA antagonists, but are not selective and are less potent than the 1 derivatives, and additionally show different structure-activity requirements for aromatic ring substitution. On the basis of these results, a model accounting for glycine receptor binding of the 1 derived antagonists is proposed, comprising (a) size-limited, hydrophobic binding of the benzene ring, (b) hydrogen-bond acceptance by the 4-oxo group, (c) hydrogen-bond donation by the 1-amino group, and (d) a Coulombic attraction of the 2-carboxylate. The model can also account for the binding of quinoxaline-2,3-diones, quinoxalic acids, and 2-carboxybenzimidazoles.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826744     DOI: 10.1021/jm00108a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.

Authors:  Daniel T Monaghan; Mark W Irvine; Blaise Mathias Costa; Guangyu Fang; David E Jane
Journal:  Neurochem Int       Date:  2012-01-17       Impact factor: 3.921

2.  Stacking interaction and its role in kynurenic acid binding to glutamate ionotropic receptors.

Authors:  Alexander V Zhuravlev; Gennady A Zakharov; Boris F Shchegolev; Elena V Savvateeva-Popova
Journal:  J Mol Model       Date:  2011-08-12       Impact factor: 1.810

3.  Region-Specific Transcriptional Control of Astrocyte Function Oversees Local Circuit Activities.

Authors:  Anna Yu-Szu Huang; Junsung Woo; Debosmita Sardar; Brittney Lozzi; Navish A Bosquez Huerta; Chia-Ching John Lin; Daniela Felice; Antrix Jain; Adriana Paulucci-Holthauzen; Benjamin Deneen
Journal:  Neuron       Date:  2020-04-21       Impact factor: 17.173

4.  Crystal structure and pharmacological characterization of a novel N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site.

Authors:  Trine Kvist; Thomas Bielefeldt Steffensen; Jeremy R Greenwood; Fatemeh Mehrzad Tabrizi; Kasper B Hansen; Michael Gajhede; Darryl S Pickering; Stephen F Traynelis; Jette Sandholm Kastrup; Hans Bräuner-Osborne
Journal:  J Biol Chem       Date:  2013-09-26       Impact factor: 5.157

5.  Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists.

Authors:  W M H Behan; T W Stone
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 6.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

Review 7.  Alternative functions of the brain transsulfuration pathway represent an underappreciated aspect of brain redox biochemistry with significant potential for therapeutic engagement.

Authors:  Kenneth Hensley; Travis T Denton
Journal:  Free Radic Biol Med       Date:  2014-11-06       Impact factor: 7.376

Review 8.  Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.

Authors:  D Zádori; P Klivényi; E Vámos; F Fülöp; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2009-07-18       Impact factor: 3.575

9.  Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity.

Authors:  B Poeggeler; A Rassoulpour; H-Q Wu; P Guidetti; R C Roberts; R Schwarcz
Journal:  Neuroscience       Date:  2007-07-16       Impact factor: 3.590

10.  Molecular electrostatic potentials in aromatic substituted 4-hydroxyquino-2-lones: glycine/NMDA receptor antagonists.

Authors:  Kaustubh A Joshi; Dinannath D Patil; Shridhar P Gejji
Journal:  J Mol Model       Date:  2008-12-09       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.